SIGLEC1 and colorectal carcinoma: In addition, the percentages of CD14+CD169+ circulating monocytes from patients with either early stage or advanced stage of CRC were significantly lower than that in TIMs from the same group of patients (P<0.00001, P<0.0001, respectively; Fig 4A).